Collectively, targeting the CD47–TSP1 axis represents a new disease-modifying therapeutic direction for AAA that could complement or delay surgical intervention and ultimately lay the foundation for the first effective pharmacological approach in AAA management. This evidence concerns the gene CD47 and triple-A syndrome.